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We are observing our 5-year anniversary, and there are many reasons to celebrate. Ourmanuscript submissions have more than tripled since 2006. In 2009, we received 800
submissions, and subsequently in 2010, the total electronic submissions numbered more than
1000, and of these, 600-plus were original articles. The average time to first decision is 21 days
for all submissions and 28 days for original articles. Because of the marked increase in original
submissions, the acceptance rate of this yearwas 35%having decreased significantly from previous
years. This reflects the improved quality of published articles in Journal of Thoracic Oncology.
The result of higher quality articles published, is a yearly increase in the impact
factor for the Journal. The first impact factor registered for 2008 was 3.5. For 2009, it was
4.55, and the 2010 impact factor will be received in June of this year. Although impact
factors are not the sole measure of a journal’s success, authors often take this into
consideration when choosing a journal for manuscript submission.
In the past year, there has been continuous improvement in the Journal of Thoracic
Oncology Web site. The homepage features a “Publish ahead of print” link for original and
review articles. We have started a “Collections” feature where all of the International
Association for the Study of Lung Cancer (IASLC) staging committee articles are listed together
and are available to anyone, member or not. Other collections include “Biostatistics for Clinicians”
and “Images of the Month.” Plans are in the works to expand these “Collections” for our Journal
of Thoracic Oncology readers. Also found on the homepage is a “Quick Poll” feature, and our
intentions are to include unknown images to test your clinical knowledge.
TheWeb site also includes a section called “Most Popular,” which lists the most viewed,
most emailed, and highest impact articles that have appeared in Journal of Thoracic Oncology.
Of note is that the top three highest impact articles were all products of the IASLC Staging
Committee. Along this line, stay tuned for the new pathology classification of adenocarcinoma
article, which will appear in February or March. This too is a product of a joint committee of
IASLC, American Thoracic Society, and European Respiratory Society and chaired by Dr.
William Travis. This promises to a landmark publication.
The Journal of Thoracic Oncology Web site has experienced an increase in traffic. In
2010, the site had approximately 19,000 visits per month, with an average of 1770 pages
viewed per day. Sixty percent of the visitors were from outside the United States, and this clearly
reflects the international nature of our organization and the Journal of Thoracic Oncology.
Although the Journal of Thoracic Oncology is making consistent progress, we certainly
do not plan to rest. It is our goal to increase readership, expand features on the Web site, and
enhance the overall quality and significance of the Journal. To achieve this goal, we are
dependent on our readers, manuscript reviewers, and authors. To our manuscript reviewers, in
particular for their dedicated hard work, we extend our sincere thanks. The complete list of
Journal of Thoracic Oncology reviewers for 2010 will be published in the March issue.
I wish to extend personal thanks to our associate editors and the superb editorial team
for the their outstanding work. The Journal of Thoracic Oncology Associate Editors, listed in
each issue of Journal of Thoracic Oncology, are leaders in their respective fields and contribute
their precious time to the success of the Journal. For this, I am deeply appreciative.
How do we make Journal of Thoracic Oncology better? Because this is your Journal,
please do not hesitate to offer ideas, suggestions, criticisms, critiques, etc. to improve the
quality of the Journal and the Web site. I value your input.
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